Ascendis Pharma Reports Strong Phase 2 Results for Achondroplasia Combination Therapy

summarizeSummary

Ascendis Pharma announced positive topline results from its COACH Phase 2 trial, demonstrating significantly improved and durable growth with its TransCon CNP and TransCon hGH combination therapy for children with achondroplasia, alongside a favorable safety profile.

check_boxKey Events

• Significant Efficacy in Phase 2 Trial

  The COACH Phase 2 trial showed a mean annualized growth velocity (AGV) of 8.80 cm/year in treatment-naïve children, with a +1.02 improvement in ACH height Z-score, indicating a tripling of efficacy compared to TransCon CNP monotherapy.

• Durable Growth and Improved Proportionality

  Combination therapy demonstrated durable growth, improvements in body proportionality, and arm span, with all children completing 52 weeks of treatment and remaining on therapy.

• Favorable Safety Profile

  Safety and tolerability were consistent with monotherapies, with generally mild treatment-emergent adverse events.

• Advancing to Phase 3

  The company has submitted a protocol and held an end-of-Phase 2 meeting with the FDA for a Phase 3 trial of the combination therapy in pediatric achondroplasia.

auto_awesomeAnalysis

Ascendis Pharma's positive topline results from the COACH Phase 2 trial represent a significant de-risking event for its achondroplasia combination therapy. The reported 'tripling of efficacy' compared to monotherapy, alongside a consistent safety profile, suggests a highly effective potential treatment for a rare disease. The progression to an end-of-Phase 2 meeting with the FDA and submission of a Phase 3 protocol indicates a clear path forward for this promising asset, enhancing the company's long-term pipeline value. Investors should monitor the upcoming PDUFA date for TransCon CNP monotherapy and further updates on the Phase 3 trial initiation.